Literature DB >> 18404389

Hyperprolactinemia.

Jaspreet Chahal1, Janet Schlechte.   

Abstract

In several respects prolactin is unique among anterior pituitary hormones. The primary regulation of prolactin secretion is mediated through hypothalamic inhibition, and the diagnosis of hyperprolactinemia can be established without the use of stimulation or suppression tests. Documenting the presence of hyperprolactinemia is not difficult-the challenge is in identifying the cause of the hormone hypersecretion. With immunoradiometric assays falsely low levels of prolactin are occasionally seen in patients with macroadenomas and very high serum prolactin (the hook effect). Macroprolactin should be suspected when a patient with hyperprolactinemia does not present with typical clinical symptoms, and all hyperprolactinemic sera should be screened for macroprolactin. With prolactinomas, prolactin levels generally parallel tumor size. Prolactin secreting macroadenomas are typically associated with levels that exceed 250 microg/l and may exceed 1,000 microg/l. Large non-functioning adenomas also lead to hyperprolactinemia but levels virtually never exceed 94 microg/l. Acquired and isolated prolactin deficiency is rare.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18404389     DOI: 10.1007/s11102-008-0107-5

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  60 in total

1.  Relation of sleep-entrained human prolactin release to REM-nonREM cycles.

Authors:  D C Parker; L G Rossman; E F Vanderlaan
Journal:  J Clin Endocrinol Metab       Date:  1974-04       Impact factor: 5.958

Review 2.  Polycystic ovary syndrome.

Authors:  S Franks
Journal:  N Engl J Med       Date:  1995-09-28       Impact factor: 91.245

3.  Serum prolactin levels in untreated primary hypothyroidism.

Authors:  K S Honbo; A J van Herle; K A Kellett
Journal:  Am J Med       Date:  1978-05       Impact factor: 4.965

4.  The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.

Authors:  S R David; C C Taylor; B J Kinon; A Breier
Journal:  Clin Ther       Date:  2000-09       Impact factor: 3.393

5.  Evaluation of endocrine tests. A: the TRH test in patients with hyperprolactinaemia.

Authors:  R Le Moli; E Endert; E Fliers; M F Prummel; W M Wiersinga
Journal:  Neth J Med       Date:  2003-02       Impact factor: 1.422

6.  Operating characteristics of the hypothalamo-pituitary-gonadal axis in men: circadian, ultradian, and pulsatile release of prolactin and its temporal coupling with luteinizing hormone.

Authors:  J D Veldhuis; M L Johnson
Journal:  J Clin Endocrinol Metab       Date:  1988-07       Impact factor: 5.958

7.  Hormonal replacement therapy in menopausal women with a history of hyperprolactinemia.

Authors:  P Touraine; C Deneux; G Plu-Bureau; P Mauvais-Jarvis; F Kuttenn
Journal:  J Endocrinol Invest       Date:  1998-12       Impact factor: 4.256

8.  The TSH response to domperidone reflects the biological activity of prolactin in macroprolactinaemia and hyperprolactinaemia.

Authors:  L P Pinto; F W F Hanna; L M Evans; J S Davies; R John; M F Scanlon
Journal:  Clin Endocrinol (Oxf)       Date:  2003-11       Impact factor: 3.478

9.  Acute prolactin release triggered by feeding.

Authors:  M E Quigley; J F Ropert; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1981-05       Impact factor: 5.958

10.  Surgical cure of prolactinoma reverses abnormal prolactin repsonse to carbidopa/L-dopa.

Authors:  M E Molitch; R H Goodman; K D Post; B J Biller; A C Moses; L W King; Z T Feldman; S Reichlin
Journal:  J Clin Endocrinol Metab       Date:  1982-12       Impact factor: 5.958

View more
  14 in total

1.  Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed.

Authors:  Gonca Tamer; Ayşegül Telci; Meral Mert; Ayse Kubat Uzum; Ferihan Aral; Refik Tanakol; Sema Yarman; Harika Boztepe; Nese Colak; Faruk Alagöl
Journal:  Endocrine       Date:  2011-09-30       Impact factor: 3.633

Review 2.  Antidepressant-induced hyperprolactinaemia: incidence, mechanisms and management.

Authors:  Flora Coker; David Taylor
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

3.  The pituitary stalk effect: is it a passing phenomenon?

Authors:  Marvin Bergsneider; Leili Mirsadraei; William H Yong; Noriko Salamon; Michael Linetsky; Marilene B Wang; David L McArthur; Anthony P Heaney
Journal:  J Neurooncol       Date:  2014-02-19       Impact factor: 4.130

Review 4.  Dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history.

Authors:  Hengxi Chen; Jing Fu; Wei Huang
Journal:  Cochrane Database Syst Rev       Date:  2016-07-25

5.  The prevalence of hyperprolactinemia in non-functioning pituitary macroadenomas.

Authors:  Fangfang Zhang; Yinxing Huang; Chenyu Ding; Guoliang Huang; Shousen Wang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 6.  Pituitary Adenomas: From Diagnosis to Therapeutics.

Authors:  Samridhi Banskota; David C Adamson
Journal:  Biomedicines       Date:  2021-04-30

Review 7.  The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.

Authors:  J Peuskens; L Pani; J Detraux; M De Hert
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

8.  Chemiluminescence systems; do all lead to same results in prolactin analysis?

Authors:  Marjan Rahnamaye Farzami; Mehri Aliasgharpour
Journal:  J Diabetes Metab Disord       Date:  2017-06-05

Review 9.  Hyperprolactinemia.

Authors:  Abha Majumdar; Nisha Sharma Mangal
Journal:  J Hum Reprod Sci       Date:  2013-07

Review 10.  Macroprolactinemia: new insights in hyperprolactinemia.

Authors:  Miro Kasum; Slavko Oreskovic; Ivana Zec; Davor Jezek; Vlatka Tomic; Vesna Gall; Goran Adzic
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.